Artificial microRNA Integration for Stable Mammalian Cell Gene Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for introducing heterologous nucleic acids into mammalian cells face inefficiencies, such as limited gene expression duration, genomic integration variability, and safety concerns, particularly with non-viral and viral vector systems, and RNA interference techniques suffer from transient effects and variable efficacy.
Innovation Solution
The use of artificial microRNAs (amiRNAs) integrated into mammalian cell genomes via transposons or viral vectors, with multiple guide strands targeting different regions of a mRNA to enhance RNA interference, ensuring stable and reliable gene suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-viral vector systems are used to introduce heterologous nucleic acids, then safety is improved, but gene expression duration is limited and efficiency is reduced
Solution Approach 1:
The patent applies preliminary action by integrating the heterologous nucleic acid into the host cell genome before the expression period begins. This genomic integration ensures that the gene of interest is permanently incorporated into the cell's genetic material, allowing for sustained expression over multiple cell divisions without the transient nature of non-integrated plasmids.
Solution Approach 2:
The patent uses a viral integrase enzyme as an intermediary to facilitate the integration of heterologous DNA into the host genome. This integrase acts as a mediator that enables efficient genomic incorporation without requiring actual viral infection, thus maintaining safety while achieving stable integration and long-term expression.
2Productivity
If viral vectors are used to introduce heterologous nucleic acids, then gene expression efficiency is improved, but safety concerns and manufacturing complexity increase
Solution Approach 1:
The patent extracts the essential function of viral vectors (genomic integration and efficient delivery) while removing the harmful components (viral infection risks). By using a non-viral system with viral-like integrase enzyme and optimized plasmid designs, the patent achieves viral-level integration efficiency without viral safety concerns.
Solution Approach 2:
The patent employs disposable, non-viral plasmid DNA molecules that can be easily manufactured and discarded after delivery. These plasmids serve as temporary delivery vehicles that get integrated into the genome, eliminating the need for complex viral manufacturing processes and associated safety containment requirements.
3Reliability
If RNA interference techniques are used to inhibit endogenous genes, then gene inhibition is achieved, but effects are transient and efficacy is variable
Solution Approach 1:
The patent applies preliminary action by integrating the RNA interference machinery (shRNA or miRNA expression cassettes) into the host cell genome before the inhibition period begins. This ensures continuous production of the inhibitory RNA molecules throughout the cell's life span, transforming transient RNA effects into permanent gene suppression.
Solution Approach 2:
The patent ensures continuity of useful action by designing genomic integration elements that enable sustained transcription of the RNA interference molecules. The integrated constructs continue to produce inhibitory RNA through multiple cell divisions, maintaining consistent gene suppression levels without requiring repeated transfections or administrations.
4Quantity of substance
If multiple copies of polynucleotide are integrated into genome, then expression levels are improved, but genomic loci variability and transcriptional silencing increase
Solution Approach 1:
The patent applies local quality by designing specific genomic target sites with particular characteristics (e.g., open chromatin regions, specific sequence motifs) that favor integration and active transcription. By directing integration to these favorable genomic locales, the patent ensures that multiple copies integrate into regions that maintain high expression levels without triggering silencing mechanisms.
Solution Approach 2:
The patent employs parameter changes by modifying the integration system to control copy number and genomic distribution. Through adjusted transposase-to-DNA ratios, repeated transposition cycles, or controlled integration conditions, the patent optimizes the number of integrated copies and their spatial distribution to maximize expression while minimizing silencing effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides stable, efficient, and reliable inhibition of endogenous genes, improving phenotypic modifications in mammalian cells, enhancing protein production and immune cell function, and addressing issues like fucosylation, lysosomal trafficking, proteolysis, and apoptosis.
Implementation Method 1
RNA interference methods may be used to inhibit endogenous mammalian cell genes in order to favorably modify the properties of the mammalian cells
Implementation Method 2
The transposase acts on the transposon to excise it from one DNA molecule and integrate it into another
Data Source
AI summary
The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.